IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma
This study has been terminated.
(Terminated by institutional review board)
Sponsor:
University of Oklahoma
Collaborator:
Midwest Medical Isotopes
Information provided by:
University of Oklahoma
ClinicalTrials.gov Identifier:
NCT00775957
First received: October 17, 2008
Last updated: September 27, 2010
Last verified: September 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A study to determine the accuracy of FLT-PET in quantifying tumor cell proliferation at the initial staging of patients with Non-Hodgkin's Lymphoma in comparison wit the "gold standard" FDG-PET.
| Condition | Intervention |
|---|---|
| Non-Hodgkin's Lymphoma | Procedure: FLT-PET scan Procedure: FDG-PET scan |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgknin's Lymphoma |
Resource links provided by NLM:
Further study details as provided by University of Oklahoma:
Primary Outcome Measures:
- Staging and ReStaging scans [ Time Frame: after hematopoetic recovery ]
| Estimated Enrollment: | 35 |
| Study Start Date: | October 2008 |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
FLT-PET Scan
|
Procedure: FLT-PET scan
imaging scan
|
|
2
FDG-PET Scan
|
Procedure: FDG-PET scan
imaging scan
|
Detailed Description:
The first primary objective reflects a necessary and preliminary requirement: to reproduce published results and validate the use of FLT-PET. In this study, 35 patients will be selected to undergoing imaging with both FLT and FDG PET.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Subjects diagnosed with lymphoma and are about to start treatment with chemotherapy
Criteria
Inclusion Criteria:
- 18 years or older
- Women must not be pregnant or breast feeding
- Histologic diagnosis of non-Hodgkin's lymphoma (any stage)
- Must undergo treatment with chemotherapy and/or radiotherapy
Exclusion Criteria:
- May not have received previous therapy with radiopharmaceuticals
- May not have received prior therapy with cytotoxic chemotherapy and/or monoclonal antibodies
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00775957
Please refer to this study by its ClinicalTrials.gov identifier: NCT00775957
Locations
| United States, Oklahoma | |
| University of Oklahoma Health Sciences Center | |
| Oklahoma City, Oklahoma, United States, 73104 | |
Sponsors and Collaborators
University of Oklahoma
Midwest Medical Isotopes
More Information
| Responsible Party: | Jennifer Holter, MD, University of Oklahoma Health Sciences Center- Dept. of Medicine |
| ClinicalTrials.gov Identifier: | NCT00775957 History of Changes |
| Other Study ID Numbers: |
FLT-NHL |
| Study First Received: | October 17, 2008 |
| Last Updated: | September 27, 2010 |
Additional relevant MeSH terms:
|
Lymphoma Lymphoma, Non-Hodgkin Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
ClinicalTrials.gov processed this record on September 21, 2017